Loading…
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $719M | $43M | $-39M | $46M | -3.6% | 8.6% | -152.2% |
| 2024 | $662M | $178M | $74M | $171M | 7.1% | 8.9% | 5512.8% |
| 2023 | $608M | $90M | $1M | $111M | 0.1% | -8.9% | -97.8% |
| 2022 | $667M | $153M | $61M | $116M | 6.9% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 667.24 | 607.52 | 661.82 | 718.95 |
| Operating Revenue | - | 667.24 | 607.52 | 661.82 | 718.95 |
| Cost Of Revenue | - | 87.22 | 83.78 | 77.91 | 74.56 |
| Gross Profit | - | 580.02 | 523.74 | 583.91 | 644.39 |
| Operating Expense | - | 534.40 | 510.34 | 508.36 | 681.25 |
| Research And Development | - | 74.55 | 91.59 | 108.80 | 106.24 |
| Selling General And Administration | - | 377.22 | 336.36 | 321.58 | 485.56 |
| Total Expenses | - | 621.62 | 594.12 | 586.26 | 755.82 |
| Operating Income | - | 45.61 | 13.40 | 75.56 | -36.86 |
| Total Operating Income As Reported | - | 46.12 | -5.27 | 81.67 | -62.28 |
| EBITDA | - | 153.36 | 90.04 | 178.28 | 42.53 |
| Normalized EBITDA | - | 152.85 | 108.72 | 172.17 | 67.95 |
| EBIT | - | 67.81 | 5.18 | 97.87 | -49.03 |
| Interest Income | - | 21.69 | 10.45 | 16.20 | 13.25 |
| Interest Expense | - | 7.07 | 2.42 | 0 | 0 |
| Net Interest Income | - | 14.62 | 8.04 | 16.20 | 13.25 |
| Other Income Expense | - | 0.51 | -18.67 | 6.11 | -25.42 |
| Interest Income Non Operating | - | 21.69 | 10.45 | 16.20 | 13.25 |
| Interest Expense Non Operating | - | 7.07 | 2.42 | 0 | 0 |
| Net Non Operating Interest Income Expense | - | 14.62 | 8.04 | 16.20 | 13.25 |
| Pretax Income | - | 60.74 | 2.77 | 97.87 | -49.03 |
| Tax Provision | - | 0.03 | 1.45 | 24 | -10.48 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -3.92 | 1.53 | -5.44 |
| Net Income Continuous Operations | - | 60.71 | 1.32 | 73.86 | -38.55 |
| Net Income From Continuing And Discontinued Operation | - | 60.71 | 1.32 | 73.86 | -38.55 |
| Net Income From Continuing Operation Net Minority Interest | - | 60.71 | 1.32 | 73.86 | -38.55 |
| Net Income | - | 60.71 | 1.32 | 73.86 | -38.55 |
| Net Income Common Stockholders | - | 60.71 | 1.32 | 73.86 | -38.55 |
| Net Income Including Noncontrolling Interests | - | 60.71 | 1.32 | 73.86 | -38.55 |
| Normalized Income | - | 60.20 | 16.07 | 69.28 | -18.57 |
| Diluted NI Availto Com Stockholders | - | 64.27 | 1.32 | 73.86 | -38.55 |
| Basic Average Shares | - | 53.67 | 54.54 | 55.10 | 56.45 |
| Diluted Average Shares | - | 61.68 | 55.51 | 55.96 | 56.45 |
| Reconciled Depreciation | - | 85.54 | 84.86 | 80.41 | 91.56 |
| Reconciled Cost Of Revenue | - | 84.31 | 81.31 | 75.47 | 72.46 |
| Total Unusual Items | - | 0.51 | -18.67 | 6.11 | -25.42 |
| Total Unusual Items Excluding Goodwill | - | 0.51 | -18.67 | 6.11 | -25.42 |
| Special Income Charges | - | 0.51 | -18.67 | 6.11 | -25.42 |
| Impairment Of Capital Assets | - | 0 | 20.19 | 0 | 0 |
| Restructuring And Mergern Acquisition | - | -0.51 | -1.52 | -6.11 | 25.42 |
| Depreciation Amortization Depletion Income Statement | - | 82.63 | 82.38 | 77.98 | 89.46 |
| Depreciation And Amortization In Income Statement | - | 82.63 | 82.38 | 77.98 | 89.46 |
| General And Administrative Expense | - | 109.43 | 107.18 | 94.29 | 196.91 |
| Other Gand A | - | 109.43 | 107.18 | 94.29 | 196.91 |
| Selling And Marketing Expense | - | 267.79 | 229.19 | 227.29 | 288.65 |
| Average Dilution Earnings | 0 | 3.56 | 0 | 0 | - |
| Amortization | - | 82.63 | 82.38 | 77.98 | 89.46 |
| Amortization Of Intangibles Income Statement | - | 82.63 | 82.38 | 77.98 | 89.46 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc.this co. | SUPN | $2.6B | -67.30 | 2.44 | -3.6% | 58.94 |
| Arcus Biosciences, Inc. | RCUS | $3.1B | -8.80 | 4.92 | -55.9% | -8.94 |
| National HealthCare Corporation | NHC | $2.9B | 24.47 | 2.75 | 11.2% | 13.71 |
| Privia Health Group, Inc. | PRVA | $2.7B | 117.50 | 3.65 | 3.1% | 50.35 |
| TransMedics Group, Inc. | TMDX |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $2.5B |
| 12.96 |
| 5.21 |
| 40.2% |
| 16.82 |
| Acadia Healthcare Company, Inc. | ACHC | $2.3B | -2.10 | 1.19 | -56.6% | -6.55 |
| Prestige Consumer Healthcare Inc. | PBH | $2.2B | 11.31 | 1.14 | 10.1% | 9.47 |
| LeMaitre Vascular, Inc. | LMAT | $2.1B | 37.03 | 5.43 | 14.7% | 25.28 |
| Select Medical Holdings Corporation | SEM | $2.0B | 13.99 | 1.20 | 8.6% | 9.20 |
| Peer Median | - | 13.47 | 3.20 | 9.3% | 11.59 | |